TITLE

Boston Sci sells most of private portfolio

AUTHOR(S)
Ford, Omar
PUB. DATE
July 2008
SOURCE
Cardiovascular Devices & Drugs;Jul2008, Vol. 14 Issue 7, p22
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of Natick, Massachusetts-based Boston Scientific to sell its investments in a portfolio of companies to secondary direct-investment firm Saints Capital. The decision came as the company intends to offset its $458 million Gudiant-related losses incurred in the fourth quarter of 2007. The sale will raise pre-tax proceeds in excess of $100 million which will be in cash and notes payable. Chief finance officer (CFO) Sam Leno states that they believe that the Saints Capital will be able to improve the portfolio.
ACCESSION #
33516935

 

Related Articles

  • Boston Sci sells most of its private portfolio for $140M. Ford, Omar // Medical Device Daily;6/20/2008, Vol. 12 Issue 119, p1 

    The article reports on a definitive agreement signed by Boston Scientific to sell its investments in a portfolio of companies, subject to certain closing and other conditions to secondary direct investment firm Saints Capital. It notes that the sale could help offset $458 million Gudiant-related...

  • Safeguard Makes Six-Pronged Exit. Schachter, Ken // Red Herring;3/3/2008, p4 

    The article reports on the decision of Safeguard Scientifics, the publicly traded venture capital fund, to sell stakes in six companies for about $100 million to Saints Capital. The deal is in line with the strategy of Safeguard Scientific to cut down a portfolio that once stood at more than 40...

  • BOSTON SCIENTIFIC. Investor's Business Daily // Investors Business Daily;4/2/2015, pA02 

    The article reports on the plan of medical device maker Boston Scientific Corp. to acquire Xlumena, an endoscopic ultrasound device manufacturer.

  • Boston Scientific Agrees to Acquire Xlumena.  // Sensors;4/10/2015, p1 

    The article reports on the definitive agreement signed by medical devices maker Boston Scientific Corp. to acquire venture-backed medical device company Xlumena Inc.

  • Boston Sci mulls sale of 2 more of its businesses to ease debt.  // Medical Technology & Devices Week;8/27/2007, Vol. 5 Issue 35, p1 

    The article discusses the addition of cardiac and vascular surgery units that will be sold by Boston Scientific in line with its plan to review its assets to strengthen its operating and financial performance. According to Paul LaViolette, COO of Boston Scientific, if the selling will push...

  • A peek inside Guidant-J&J-Boston Scientific drama. Andrews, Greg // Indianapolis Business Journal;12/19/2005, Vol. 26 Issue 42, p4 

    The article looks into the high profile competitive bids between Johnson & Johnson with Boston Scientific Corp. for the control of Guidant Corp. in the U.S. Negotiations for the consolidation and merger of Guidant have been intense. The highlights of the negotiation between Boston Scientific...

  • Boston Sci mulls sale of 2 more of its businesses to ease debt. Johnson, Holland // Medical Device Daily;8/20/2007, Vol. 11 Issue 158, p1 

    The article reports on the decision of Boston Scientific to include its cardiac and vascular surgery units to the list of businesses that the company is selling. The decision is related to the efforts of the company to reduce its debts. According to Paul LaViolette, COO of Boston Scientific, the...

  • Boston Sci sells EVAR unit for $30 million plus minority stake.  // Medical Device Daily;4/1/2008, Vol. 12 Issue 63, p1 

    The article reports that Boston Scientific sold Boston Scientific Santa Rosa to TV2 Holding. The sale includes equipment and intellectual property related to the TriVascular endovascular aortic repair (EVAR) program. Jim Tobin, president and chief executive officer (CEO) of Boston Scientific,...

  • Boston Scientific closes sale of 2 units to Avista for $425 million.  // Medical Device Daily;2/15/2008, Vol. 12 Issue 32, p1 

    The article reports on the completion of the sale of Boston Scientific's Fluid Management and Venous Access businesses to Avista Capital Partners. Boston claims that the sale has divested all five nonstrategic units it had previously planned to divest and it expects to record an after-tax gain...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics